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Purpose: Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) is a key enzyme 
in the androgen biosynthesis pathway. CYP17A1 has been focused on because of the 
promising results of a potent CYP17A1 inhibitor in the treatment of castration-re-
sistant prostate cancer (CRPC). A hypothesis that intratumoral androgenesis may play 
a role in the progression of CRPC has recently been postulated. Thus, we evaluated 
whether commonly used prostate cancer cell lines express CYP17A1.
Materials and Methods: Androgen-sensitive LNCaP and androgen-insensitive PC-3 
and DU145 cells were used. To evaluate the expression of CYP17A1 protein and RNA, 
we performed Western blotting and RT-PCR, respectively. 
Results: We were unable to detect either CYP17A1 protein or RNA in any of the cell 
lines tested. We failed to detect any expression of CYP17A1, despite several repetitions 
of these techniques under different conditions.
Conclusions: The expression of CYP17A1 protein and RNA in LNCaP, PC-3, and DU145 
cells appears to be either absent or too low for detection. The mechanism of action of 
abiraterone acetate, a CYP17A1 inhibitor, may be related more to adrenal androgen 
blockade than to intratumoral androgenesis. 
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INTRODUCTION
In Western countries, prostate cancer (PC) is the most com-
monly diagnosed cancer and represents the second leading 
cause of death in male cancer patients [1]. In Korea, PC is 
the fifth most common cancer and the most rapidly increas-
ing cancer in men in terms of incidence [2]. In particular, 
PCs in Korea tend to have higher Gleason scores and to be 
of a more advanced stage than those found in Western coun-
tries [3]. Patients with localized PC can be cured through 
treatment by radical prostatectomy or radiation therapy; 
however, 10% to 30% of these men experience biochemical 
recurrence. The standard treatment for patients with ad-
vanced or metastatic PC has been androgen deprivation 
therapy because androgens play a vital role in the develop-
ment, growth, and progression of PC [4]. Nonetheless, PC 
in this state is incurable; it eventually progresses to castra-
tion-resistant PC (CRPC) [5]. A second-line treatment with 
docetaxel chemotherapy combined with prednisone is only 
temporarily effective, providing a 2- or 3-month survival 
benefit [6,7].
　Recently, abiraterone acetate, which is a potent inhibitor 
of cytochrome P450 17α-hydroxylase/17,20-lyase (CYP-
17A1), has been focused on for the treatment of CRPC. 
CYP17A1 is a key enzyme in the androgen biosynthesis 
pathway, which functions in the testes and adrenal glands 
to catalyze the conversion of pregnenolone and progester-
one into the weak androgens dehydroepiandrosterone and 
androstenedione, respectively [8-10]. Early clinical trials 
demonstrated that abiraterone acetate has a significant 
and sustained antitumor activity in post-docetaxel CRPC 
[11-14]. The theoretical mechanism is that androgen-acti-
vating ligands originating in the adrenal glands or occur-
ring by endogenous synthesis may be activating CRPC. Korean J Urol 2011;52:494-497
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FIG. 1. Western blot for CYP17A1 in prostate cancer cell lines. FIG. 2. RT-PCR for CYP17A1 in prostate cancer cell lines.
Much evidence indicates that CRPC can synthesize an-
drogen from cholesterol [15]. Compared with primary pros-
tate tumors, metastatic CRPC displays alterations in the 
genes encoding steroidogenic enzymes, including the 
up-regulated expression of CYP17A1 [16]. However, com-
pared with the promising results from clinical trials, evi-
dence is lacking from in vitro and in vivo studies for the mo-
lecular mechanism behind the response to abiraterone 
acetate.
　In this study, we evaluated whether commonly used 
prostate cancer cell lines express CYP17A1 as a part of ba-
sic research to understand the molecular pathophysiology 
of prostate cancer treatments.
MATERIALS AND METHODS
1. Cell lines and culture
Human prostate cancer cell lines were purchased from the 
Korean Cell Line Bank (KCLB, Seoul, Korea). Androgen- 
sensitive LNCaP and androgen-insensitive PC-3 and 
DU145 cells were used in the experiments. The culture me-
dium used throughout these experiments was DMEM 
(GibcoBRL, USA) containing 10% heat-inactivated fetal 
bovine serum (FBS; Mediatech, USA), 2 mm L-glutamine, 
100 units/ml penicillin, and 100 μg/ml streptomycin. Cells 
were grown as monolayer cultures and were maintained at 
37
oC under a humidified atmosphere of 5% CO2 in air. To 
retain the original properties of the cells, experiments were 
performed with cell lines at passage numbers within the 
range of 5 to 40.
2. Western blot analysis
Cells were lysed in 500 μl of cell lysis buffer (1 M Tris-Cl, 
pH 7.4, 0.5 M NaCl, and 0.5 M EDTA) supplemented with 
the protease inhibitor pepstatin (0.7 mg/ml). Cell lysates 
were centrifuged at 14,000 rpm for 15 minutes at 4
oC. Total 
protein (30 mg) was resolved on 10% SDS-polyacrylamide 
gels, transferred to polyvinylidene difluoride membranes, 
and blocked with 5% skim milk in 1% Tween-20/TBS. The 
membranes were incubated with a rabbit polyclonal an-
ti-CYP17A1 antibody (NB100-92420; Novus Biological, 
USA) overnight. The membranes were washed and then in-
cubated for 1.5 hours with secondary antibodies, and pro-
tein expression was detected with an ECL developing kit.
3. RT-PCR
Total RNA was extracted by using the RNeasy kit (Qiagen, 
Germany) according to the manufacturer's protocol. 
Aliquots of 1 μg of total RNA were used for complementary 
DNA (cDNA) synthesis with a reverse transcription sys-
tem (Promega, Madison, WI, USA) and oligo (dT) in a total 
reaction volume of 20 μl. The primer sequences used for 
PCR were 5'-AGCTCGTGGCTCTCTTGCTG-3' (forward) 
and 5'-CGCGATGTCTAGAGTTGCCA-3' (reverse). The 
optimal PCR conditions were determined on the basis of the 
amount of amplification product in proportion to the 
amount of input RNA. The thermal profile was 95
oC for 5 
minutes, 95
oC for 30 s, and the appropriate annealing tem-
perature for 30 s for a total of 30 cycles, and a final extension 
at 72
oC for 7 minutes. The annealing temperature varied 
between 57
oC and 62
oC. The PCR products were electro-
phoresed on a 1% agarose gel and were visualized by ethi-
dium bromide staining and UV irradiation.
RESULTS
No expression of CYP17A1 was detected in any of the cell 
lines analyzed by Western blot despite CYP17A1 detection 
in a positive control cell line (HeLa cells) (Fig. 1). According 
to the manufacturer's protocol, the protein product is ex-
pected to be detected at approximately 48 kDa. However, 
we could not find any expression, even after altering the 
procedural conditions several times. The CYP17A1 mRNA 
was also not detected by RT-PCR in any of the cell lines test-
ed (Fig. 2). The mRNA for CYP17A1 is assumed to be 307 
bp in length, but we could not detect it despite several repe-
titions of RT-PCR. In contrast, the expression of CYP17A1 
mRNA in HeLa cells was confirmed by RT-PCR.
DISCUSSION
Abiraterone acetate is a potent, selective, and irreversible 
inhibitor of CYP17A1 (IC50, 2-4 nmol/l) [17]. Abiraterone Korean J Urol 2011;52:494-497
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acetate is 10- to 30-fold more potent than the nonselective 
inhibitor ketoconazole. CYP17A1 plays a key role in an-
drogen biosynthesis, functioning in both the conversion of 
pregnenolone to 17-α-hydroxypregnenolone (via a 17-α- 
hydroxylase) and the subsequent conversion of this moiety 
to dehydroepiandrosterone (DHEA) via a 17,20-lyase. 
CYP17A1 also converts progesterone to 17-α-hydrox-
yprogesterone and finally to androstenedione [8-10]. These 
androgenesis steps could be occurring in the testes and 
adrenal glands. DHEA and androstenedione may be con-
verted to testosterone and consequently to dihydrotes-
tosterone (DHT), which is a more potent androgen in pe-
ripheral tissues.
　The primary concern regarding androgens and androgen 
receptors (ARs) in CRPC is that prostate-specific antigen 
(PSA) is still a prognostic surrogate in CRPC patients. The 
production of PSA requires activated ARs because the pro-
moter region of the PSA gene contains androgen-re-
sponsive elements. Extensive evidence suggests that the 
AR plays a key role in cell proliferation in CRPC. There is 
an approximate 30% overexpression of the AR gene and 
protein after the conversion of PC to CRPC [18]. Further-
more, the sensitivity of the AR itself is much higher in 
CRPC cells, and the DHT level required for the pro-
liferation of CRPC cells is approximately one quarter of 
that required for androgen-dependent cells [19]. Thus, the 
original rationale for the use of abiraterone acetate in 
CRPC is that a complete blockade of not only testicular but 
also adrenal androgen may beneficial in CRPC patients.
　Furthermore, many studies of DHT in CRPC prostate 
tissues showed relatively maintained levels of DHT de-
spite castration levels of serum testosterone. Mohler et al 
claimed that the level of androgen in CRPC prostate tissues 
was the same as that in normal benign hyperplastic pros-
tate tissue, and this level was about 80% of that observed 
in patients who did not undergo androgen deprivation [20]. 
Nishiyama et al reported similar data [21]. This phenom-
enon has been explained by the up-regulation of 5α-reduc-
tase activity in CRPC.
　A great deal of evidence has been published on endoge-
nous androgenesis in cancer cells. Compared with primary 
prostate tumors, metastatic lesions of CRPC display 
up-regulation of genes encoding steroidogenic enzymes, in-
cluding CYP17A1, FASN, HSD3B1, HSD17B3, CYP19A1, 
and UGT2B17. Additionally, intratumoral testosterone 
levels were higher than those observed in the primary tu-
mors of eugonal patients [16]. Furthermore, recent study 
has demonstrated a “backdoor pathway” for the synthesis 
of DHT [15]. This backdoor pathway can produce DHT 
without requiring the steps of testosterone synthesis as an 
alternative to the “classic pathway” of androgenesis. In this 
DHT synthesis backdoor pathway, CYP17A1 also plays a 
major role. Thus, abiraterone acetate has been expected to 
block not only testicular and adrenal androgenesis but also 
intratumoral de novo androgen synthesis.
　In clinical trials, the therapeutic effectiveness of abir-
aterone acetate in CRPC patients appears very promising. 
Phase I studies have reported that abiraterone acetate was 
safe and resulted in a ＞50% suppression of baseline testos-
terone in noncastrated patients [13]. Subsequently, sev-
eral phase I and II studies have demonstrated that more 
than 50% of patients had a ＞50% PSA response in various 
settings, such as chemotherapy-naïve or post-docetaxel pa-
tients [11,12,14,22]. The encouraging data from these early 
experiences led to phase III studies, COU-AA-301. This tri-
al was initiated in April of 2008 with a total of 1195 patients 
with docetaxel-refractory CRPC who were randomly as-
signed to either abiraterone acetate or placebo in a 2:1 fash-
ion (both study arms received concomitant prednisone 
therapy). Following a protocol-specified interim analysis 
in August 2010, an independent data monitoring commit-
tee recommended that the study be unblinded because the 
treatment with abiraterone resulted in an improvement in 
overall survival from 10.9 to 14.8 months (HR 0.646, p＜ 
0.0001) [23].
　In contrast to this clinical success, the exact mechanism 
of drug action remains unknown. Evidence from cell line 
or animal studies is very limited. We initially planned to 
prove the molecular basis of the steroidogenic and con-
sequently oncologic effect of CYP17A1 in PC cell lines. 
However, we could not detect either the protein or the RNA 
of CYP17A1 in commonly used PC cells (LNCaP, PC-3, and 
DU145). This may be due to technical problems; however, 
it is more likely that the CYP17A1 protein and its RNA are 
absent in the cell lines we used or that the levels were too 
low to reproducibly detect. The report by Locke et al regard-
ing the backdoor pathway showed the presence of both 
CYP17A1 protein and RNA in LNCaP tumors using a xeno-
graft model [15]. Dillard et al showed the expression of 
CYP17A1 protein and RNA in PC-3 and DU145 cells. They 
also demonstrated that LNCaP cells at passage numbers 
less than 33 (LNCaP-C33) did not express CYP17A1, 
whereas cells at passage numbers over 80 (LNCaP-C81) ex-
pressed CYP17A1 [24]. LNCaP-C33 is considered to be an 
androgen-dependent cell line, whereas LNCaP-C81 is con-
sidered to be androgen-independent. In contrast, Hofland 
et al argued that the majority of tumor samples showed low 
or absent mRNA expression for steroidogenic enzymes re-
quired for de novo steroid synthesis [25]. Simultaneous but 
low expression of the enzymes CYP17A1 and 3β-hydrox-
ysteroid dehydrogenase (HSD3B1), which are essential for 
the synthesis of androgens, could be detected in 19 of 88 pa-
tient samples. Of the 19 CRPC tissues examined, only 5 
samples expressed both enzymes. Additionally, the ex-
pression of both enzymes was only detectable at very low 
levels in the two androgen-responsive cell lines (VCaP and 
DuCaP) and in only 2 out of 13 androgen-dependent 
xenografts. They also could not detect CYP17A1 RNA in 
LNCaP or PC346C cells. These authors concluded that in-
tratumoral steroid biosynthesis contributes less than cir-
culating adrenal androgens, implying that blocking an-
drogen production and its intraprostatic conversion into 
DHT, such as via CYP17A1 inhibition, may represent fa-
vorable therapeutic options in patients with CRPC. The re-Korean J Urol 2011;52:494-497
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sults of our study support Hofland’s argument. No ex-
pression of CYP17A1 protein or mRNA was detected in any 
of the original cell lines tested. Thus, in our opinion, 
CYP17A1 expression in PC cell lines might be absent or ex-
tremely low, and it may not be reproducibly detectable and 
will likely have little clinical implication.
CONCLUSIONS
In conclusion, the expression of CYP17A1 protein and RNA 
in LNCaP, PC-3, and DU145 PC cell lines appears to be ab-
sent or too low to easily detect. Consequently, the mecha-
nism of action of abiraterone acetate, a CYP17A1 inhibitor, 
may be related more to adrenal androgen blockade than to 
the blockade of intratumoral androgenesis. 
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